Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

proximately 3.2 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the liver, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. Most infected individuals are unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology.
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015 Today, humanity takes a ... the singularity, and fat-free cronuts: 1-800 CONTACTS announces their new ... in just two taps. Two taps. New contacts. ... The app also features LensGauge which helps keep ... when you need to reorder. "Since our inception, ...
(Date:4/24/2015)... April 24, 2015  A new study shows an "alarming ... drugs used to slow the progression of multiple sclerosis or ... by researchers at Oregon Health & Science University (OHSU) and ... the number of MS drugs in the marketplace over the ... stabilized costs for patients who use those drugs. Researchers found ...
(Date:4/24/2015)... S.C. , April 24, 2015  Span-America ... plans to release its fiscal 2015 second quarter ... regular trading. The company will conduct ... Friday, May 1, to review the company,s financial and ... 2015.  A live broadcast of the conference call ...
Breaking Medicine Technology:Attention: We live in the future. Order contact lenses from your wrist with the 1-800 CONTACTS app for Apple Watch 2Researchers find alarming rise in cost of MS drugs over past two decades 2Researchers find alarming rise in cost of MS drugs over past two decades 3Researchers find alarming rise in cost of MS drugs over past two decades 4
... influenza,transmission patterns in the Southern Hemisphere and ... finding that,each season influenza travels from low ... populated centers. Their work, funded by the,Fogarty ... Institutes,of Health (NIH), can improve planning for ...
... - An overexpressed protein,protects human pancreatic cancer ... of the body's natural defenses against,out-of-control cell growth, ... Cancer Center report in the March issue of ... by the abbreviation,TG2, previously has been found by ...
Cached Medicine Technology:Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 2Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 3Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3
(Date:4/25/2015)... 25, 2015 By definition, a CIO’s responsibility ... the enterprise relying on their judgement and expertise to keep ... according to an article published in National Mortgage News ... be doing a disservice to their responsibilities by focusing too ... t’s are crossed when it comes to company policy and ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 Parker and Sons ... and cooling, has spiked in Arizona alongside the growing economy. ... additional forty employees for April to help account for the ... forty employees in April is something we are enthusiastic about. ... said Paul Kelly, president at Parker and Sons. , Indeed, ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI ... event in the nation! This year, on May 5th, 2015, ... to take DI Day on the road by supporting the ... ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants ... the change by stating, "The first Twin Cities DI Day ...
(Date:4/24/2015)... 24, 2015 As the nation recognizes ... unique sacrifices of these young men and women, the ... Veterans and their Families” presents a special training session ... to gain a better understanding of the effect of ... For those – civilian and military – who provide ...
(Date:4/24/2015)... 2015 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... federal multidistrict litigation underway in U.S. District Court, ... the parties involved in the proceeding submitted a ... other things, preparation for the litigation’s upcoming bellwether ... plaintiffs and defendants have conducted depositions of non-party ...
Breaking Medicine News(10 mins):Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... transplants after removing small cancerous and benign masses from ... December issue of the urology journal BJUI. The ... of Maryland School of Medicine in Baltimore, could offer ... as well as increasing the supply of viable organs. ...
... Nutra Pharma ... the Food and Drug Administration (FDA). This registration is considered the final step required by ... the treatment of chronic pain. , ... Plantation, FL (Vocus) December 7, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology ...
... ... Changes in Industry Standards and Compliance Requirements , ... (PRWEB) December 7, 2009 -- BridgeGate ... the launch of its new integration technology training program, which will kick off ...
... in comparison study , SUNDAY, Dec. 6 (HealthDay ... therapy for prostate cancer are best controlled by ... according to a new study. , Androgen suppression ... prostate cancer, but about 80 percent of patients ...
... older anti-clotting drug, with fewer hassles, study finds , MONDAY, ... dabigatran etexilate may be just as effective in preventing dangerous ... for doctors and patients to manage, a new study finds. ... in Europe; it is not yet approved for use in ...
... ... offer top-of-the-line implementation services to Talyst’s clients in the acute care industry. ... (PRWEB) ... of the American Society of Health-System Pharmacists in Las Vegas, Talyst announced a ...
Cached Medicine News:Health News:Controversial kidney transplant technique could provide lifeline for very ill patients 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 2Health News:BridgeGate International Announces New Integration and Interoperability Training Program 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 4Health News:Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2
... Bard PerFix plug technique, recommended for ... recurrent indirect and direct inguinal hernias, ... suture technique, requiring less overall dissection ... tension-free repair technique. The result is ...
... Laser System is a compact, highly portable, ... Its unique, integrated StarPulse feature enables the ... on the leg and face, and pigmented ... also be used as a continuous wave ...
... The Gemini is the newest addition ... With two distinct wavelengths to choose from, ... stands out in an exploding non-invasive aesthetic ... versatility, speed and effectiveness while maintaining the ...
... The 800 Series KTP/YAG™ Surgical ... hospital market. It is a high-power, ... ENT, plastic surgery, orthopedics, general surgery, ... The KTP/532™ beam surgically cuts, vaporizes ...
Medicine Products: